Document is current
Any future updates will be listed below
-
Authors
Yan, Jing
Yang, Xiaohui https://orcid.org/0009-0009-6047-4682
Li, Guilin
Ramirez, Omar A. https://orcid.org/0000-0002-9326-2290
Hagenston, Anna M. https://orcid.org/0000-0001-7747-5336
Chen, Zhe-Yu https://orcid.org/0000-0002-7092-8723
Bading, Hilmar https://orcid.org/0000-0003-0258-4348
- License Information
-
More Information
Article History
Received: 30 January 2025
Revised: 3 July 2025
Accepted: 29 July 2025
First Online: 26 August 2025
Competing interests
: HB and JY are named inventors of the patent application for a novel class of neuroprotectants (PCT/EP2018/078577); HB is founder of FundaMental Pharma GmbH, Heidelberg, Germany, which licenses FP802. HB and JY are shareholders of FundaMental Pharma GmbH. Other authors report no competing interests.
: All animal procedures were approved by the Ethical Committee of the School of Basic Medical Sciences, Shandong University (Approval Number: ECSBMSSDU2021-2-111) or by the Regierungspräsidium Karlsruhe (Approval Number: 35-9185.81/G-167/19), and were performed in strict accordance with the committees’ relevant guidelines and regulations.
